321 related articles for article (PubMed ID: 28284752)
61. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease.
Smith MP; Cass WA
Neurosci Lett; 2007 Feb; 412(3):259-63. PubMed ID: 17125923
[TBL] [Abstract][Full Text] [Related]
62. Pyruvate protects cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the Akt signaling pathway and increasing glutathione peroxidase expression.
Fernandez-Gomez FJ; Pastor MD; Garcia-Martinez EM; Melero-Fernandez de Mera R; Gou-Fabregas M; Gomez-Lazaro M; Calvo S; Soler RM; Galindo MF; Jordán J
Neurobiol Dis; 2006 Nov; 24(2):296-307. PubMed ID: 16978869
[TBL] [Abstract][Full Text] [Related]
63. Protective activity of guanosine in an in vitro model of Parkinson's disease.
Giuliani P; Romano S; Ballerini P; Ciccarelli R; Petragnani N; Cicchitti S; Zuccarini M; Jiang S; Rathbone MP; Caciagli F; Di Iorio P
Panminerva Med; 2012 Dec; 54(1 Suppl 4):43-51. PubMed ID: 23241934
[TBL] [Abstract][Full Text] [Related]
64. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
65. Rhododendrin-Induced RNF146 Expression via Estrogen Receptor β Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
Kim H; Park J; Leem H; Cho M; Yoon JH; Maeng HJ; Lee Y
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30974833
[TBL] [Abstract][Full Text] [Related]
66. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
67. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
68. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
69. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
[TBL] [Abstract][Full Text] [Related]
70. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
71. Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease.
Ribeiro RP; Moreira EL; Santos DB; Colle D; Dos Santos AA; Peres KC; Figueiredo CP; Farina M
Neurochem Res; 2013 Mar; 38(3):660-8. PubMed ID: 23334712
[TBL] [Abstract][Full Text] [Related]
72. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease.
Morroni F; Tarozzi A; Sita G; Bolondi C; Zolezzi Moraga JM; Cantelli-Forti G; Hrelia P
Neurotoxicology; 2013 May; 36():63-71. PubMed ID: 23518299
[TBL] [Abstract][Full Text] [Related]
73. Secretome released from hydrogel-embedded adipose mesenchymal stem cells protects against the Parkinson's disease related toxin 6-hydroxydopamine.
Chierchia A; Chirico N; Boeri L; Raimondi I; Riva GA; Raimondi MT; Tunesi M; Giordano C; Forloni G; Albani D
Eur J Pharm Biopharm; 2017 Dec; 121():113-120. PubMed ID: 28965958
[TBL] [Abstract][Full Text] [Related]
74. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
[TBL] [Abstract][Full Text] [Related]
75. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
Manáková S; Singh A; Kääriäinen T; Taari H; Kulkarni SK; Männistö PT
Brain Res; 2005 Mar; 1038(1):83-91. PubMed ID: 15748876
[TBL] [Abstract][Full Text] [Related]
76. Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: neuroprotection by serotonin, GABA and bone marrow cells supplementation.
Kuruvilla KP; Nandhu MS; Paul J; Paulose CS
J Neurol Sci; 2013 Aug; 331(1-2):31-7. PubMed ID: 23726276
[TBL] [Abstract][Full Text] [Related]
77. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
[TBL] [Abstract][Full Text] [Related]
78. Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson's disease.
Yin SM; Zhao D; Yu DQ; Li SL; An D; Peng Y; Xu H; Sun YP; Wang DM; Zhao J; Zhang WQ
Sheng Li Xue Bao; 2014 Dec; 66(6):658-66. PubMed ID: 25516514
[TBL] [Abstract][Full Text] [Related]
79. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress.
Baluchnejadmojarad T; Roghani M; Mafakheri M
Neurosci Lett; 2010 Aug; 480(3):206-10. PubMed ID: 20600617
[TBL] [Abstract][Full Text] [Related]
80. Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.
Walsh S; Gavin A; Wyatt S; O'Connor C; Keeshan K; Nolan YM; O'Keeffe GW; Sullivan AM
Int J Neurosci; 2015 Jan; 125(1):70-7. PubMed ID: 24628580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
